Search: 4300 news

AI-based technology developed by a São Paulo startup supported by FAPESP is in use at Albert Einstein Jewish Hospital to reduce the risk of coronavirus transmission

Selected projects aim to repurpose existing drugs for treatment of COVID-19, find novel compounds with therapeutic potential and develop alternative diagnostic methods. The call remains open until June 22.

Brazilian researchers show that the activity of the gene TRIB3 in lung cells declines in men as they age. Compounds capable of reversing the process could be tested against the novel coronavirus.

To develop a drug capable of treating the disease caused by the novel coronavirus, a research institution in São Paulo will deploy a platform used to produce monoclonal antibodies against tetanus and zika.

The review article by researchers at the University of São Paulo shows the advantages of this technological alternative, which is nontoxic and much cheaper than other methods.

Diagnostic strategy developed by Brazilian researchers can also be used to distinguish MS from neuromyelitis optica, another demyelinating disorder. The two diseases have similar symptoms but must be treated differently.

Based in São Paulo, Magnamed will produce 6,500 ventilators by August for use in treating COVID-19 patients, working in partnership with a pool of leading Brazilian and multinational corporations.

The initiative is coordinated by Butantan Institute and includes units in several cities accredited by Adolfo Lutz Institute (IAL), the regional reference laboratory. Short supply is the main bottleneck delaying the expansion of testing in the state.

Researchers at the University of Campinas are organizing professionals, supplies and equipment to test for COVID-19, understand how the virus works, identify existing drugs that are effective against the disease, and use 3D printing to produce parts for ventilators and personal protective equipment.

Scientists affiliated with the FAPESP-funded Center for Cell-Based Therapy have collected plasma from donors and are conducting a trial to check the safety and effectiveness of passive immunization.

Electrical impedance tomography system developed by startup based in São Paulo minimizes complications associated with mechanical ventilation and is used in the treatment of COVID-19 by hospitals in Italy, Spain and the US.

Species never before found in humans described in PLOS ONE belong to the genera Ambidensovirus and Chapparvovirus. Researchers do not yet know if they can cause disease.

Groundbreaking study shows that regular exercise in prepubertal childhood improves the functioning of cells essential to vascular health. Babies weighing less than 2.5 kg at birth are more likely to develop cardiovascular diseases in adulthood.

Metabolic changes associated with diseases such as pulmonary hypertension and chronic obstructive pulmonary disease may reprogram gene expression to increase production of a protein used by SARS-CoV-2 to penetrate lung cells.

Research by the FAPESP-funded Center for Metropolitan Studies (CEM) shows that it is not feasible to separate high-risk groups in low-income communities, where the majority of the Brazilian population live. The problem is especially acute in the Southeast region, with metropolitan São Paulo displaying the largest deficit.

Brazilian researchers use minimally invasive technique to perform autopsies on deceased patients diagnosed with COVID-19, with the aim of assisting physicians and other health workers.

One of the studies will evaluate the effectiveness of drugs that inhibit bradykinin against pulmonary inflammation in critical patients. The other will analyze the transmission dynamics of the novel coronavirus in a small town in Amazonia.

At an event organized by FAPESP and the UK’s Royal Society, researchers showed how partnerships are important in producing scientific results at the knowledge frontier.

A population study conducted at a regional center of the state of São Paulo (Brazil) showed that 32.9% of subjects under 40 had no immunity against the disease, compared with only 1% in those over 50.

Research and higher-education institutes from the state of São Paulo have signed an agreement with the Oak Ridge National Laboratory, an institution associated with United States Energy Department with great experience in managing atmospheric data; the initiative’s goal is to make knowledge generated with public funding accessible.

Tool developed by a firm supported by FAPESP is being used to assess student learning in primary and secondary schools in the state of São Paulo.

Scientists in the state of São Paulo are working on a method of diagnosing the disease quickly and cheaply by combining an analysis of the pattern of molecules in body fluids with machine learning.

Researchers explains how their experience with the Zika virus, made possible with funding from FAPESP, helped them to cultured the SARS-CoV-2 coronavirus.

Scientists at Brazil’s National Energy and Materials Research Center are analyzing the antiviral action of commercially available drugs in cultured cells.

A formulation developed in Brazil is expected to protect against all 90-odd serotypes of the Streptococcus pneumoniae bacterium. Vaccines currently available in Brazil are effective against 13 serotypes at most.

As one of the Engineering Research Centers supported by FAPESP, the new center will focus on R&D for next-generation deep-sea oil production systems.

The purpose of the agreement is to promote and deepen scientific and technological cooperation between researchers from São Paulo and the US Department of Energy’s high-energy physics laboratory.

Study by researchers at Brazil’s National Disaster Surveillance and Early Warning Center (CEMADEN) also shows a rise in the number of consecutive dry days, suggesting that extreme rainfall events are concentrated in shorter, more widely spaced periods.

In contrast with China and other countries where the disease spread slowly, in Brazil more than 300 people started the epidemic. Most were passengers flying in from Italy.

In animal testing, experimental Ebola vaccine based on platform developed by US pharmaceutical company in partnership with Brazilian researchers conferred immunity against hemorrhagic virus with single dose.